Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18022163 | 0.88 | ALDH1A1 (0.45) | MAPTCYP3A4CYP2C19LMNA | |
| SCHEMBL17826331 | 0.80 | LMNA (0.35) | CYP3A4CYP2C19ABCB11LMNAPTGS1 | |
| SCHEMBL18023679 | 0.80 | LMNA (0.35) | CYP3A4CYP2C19ABCB11LMNAPTGS1 | |
| SCHEMBL18022189 | 0.80 | LMNA (0.35) | CYP3A4CYP2C19ABCB11LMNAPTGS1 | |
| SCHEMBL23593366 | 0.78 | POLB (0.34) | MAPTCYP3A4CYP2C19 | |
| SCHEMBL10714782 | 0.78 | POLB (0.34) | MAPTCYP3A4CYP2C19 | |
| SCHEMBL18022160 | 0.77 | LMNA (0.42) | CYP3A4CYP2C19LMNA | |
| SCHEMBL18034140 | 0.75 | LMNA (0.47) | MAPTCYP3A4CYP2C19LMNA | |
| SCHEMBL18022141 | 0.75 | LMNA (0.47) | MAPTCYP3A4CYP2C19LMNA | |
| SCHEMBL17826329 | 0.75 | MAPT (0.33) | MAPTCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2958883-B1 | CYCLOHEXENONE COMPOSITIONS AND PROCESS FOR MAKING THEREOF | GOLDEN BIOTECHNOLOGY CORP (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20160251308-A1 | Cyclohexenone Compositions and Process for Making Thereof | GOLDEN BIOTECHNOLOGY CORP (US) | 2016-09-01 | — | — | US | disclosed |
| US-20160251308-A1 | Cyclohexenone Compositions and Process for Making Thereof | GOLDEN BIOTECHNOLOGY CORP (US) | 2016-09-01 | — | — | US | disclosed |
| WO-2016133940-A1 | ANTICANCER AGENTS AND PROCESS OF MAKING THEREOF | GOLDEN BIOTECHNOLOGY CORPORATION (US) | 2016-08-25 | — | — | WO | disclosed |
| US-20160237012-A1 | ANTICANCER AGENTS AND PROCESS OF MAKING THEREOF | GOLDEN BIOTECHNOLOGY CORPORATION | 2016-08-18 | — | — | US | disclosed |
| US-20160237012-A1 | ANTICANCER AGENTS AND PROCESS OF MAKING THEREOF | GOLDEN BIOTECHNOLOGY CORPORATION | 2016-08-18 | — | — | US | disclosed |
| US-9365481-B2 | Cyclohexenone compositions and process for making thereof | GOLDEN BIOTECHNOLOGY CORPORATION (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365481-B2 | Cyclohexenone compositions and process for making thereof | GOLDEN BIOTECHNOLOGY CORPORATION (US) | 2016-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237012-A1 | ANTICANCER AGENTS AND PROCESS OF MAKING THEREOF | MCL1, HCCS, CASP3 | MAPT 3911/4885CYP3A4 185/4885CYP2C19 1324/4885 |
| US-20160251308-A1 | Cyclohexenone Compositions and Process for Making Thereof | HSD17B7, CYP17A1, CYP51A1 | MAPT 4072/4885CYP3A4 25/4885CYP2C19 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.